Beta Bionics reports developments for a commercial-stage medical device company focused on diabetes management for insulin-requiring people. Its core product, the iLet Bionic Pancreas, uses adaptive closed-loop algorithms and is an FDA-cleared insulin delivery device that autonomously determines insulin doses.
Company news commonly covers quarterly financial results and guidance, net sales through Durable Medical Equipment and Pharmacy Benefit Plan channels, new patient starts, product software such as Bionic Insights within Bionic Reports, and diabetes-technology development programs including the Mint patch pump and bihormonal system.
Beta Bionics (BBNX) plans to release its third-quarter 2026 financial results after markets close on October 27, 2026. Management will review the quarter on a conference call and webcast at 4:30 p.m. Eastern Time that day. A replay will be archived on the company’s investor website.
Beta Bionics (BBNX) announced a partnership to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ Eversense 365 continuous glucose monitoring system. Commercial launch of the integrated iLet and Eversense 365 offering is expected in the fourth quarter of 2026, subject to completion of the integration. At launch, Beta Bionics expects iLet to support the broadest range of CGM manufacturer options among automated insulin delivery systems, aiming to maximize device choice for users. The companies have also committed to a future integration of the mint system with Eversense 365, combining adaptive insulin dosing with year-long glucose sensing.
Beta Bionics (BBNX) closed an underwritten public offering of common stock and pre-funded warrants, generating aggregate gross proceeds of $172.5 million before fees and expenses.
The company sold 7,652,175 shares of common stock at $17.25 per share and, to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at $17.2499 per warrant. Underwriters fully exercised their option to buy an additional 1,304,348 shares of common stock. Beta Bionics expects to use the net proceeds for general corporate purposes, including commercialization of its Mint™ product, expansion of manufacturing facilities, research and clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses. J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners served as joint book-running managers.
Beta Bionics (BBNX) priced an underwritten public offering of 7,652,175 common shares at $17.25 and pre-funded warrants for 1,043,484 shares at $17.2499 per warrant, expected to raise gross proceeds of $150.0 million before fees. The offering is expected to close on or about September 17, 2026, subject to customary conditions, and underwriters have a 30-day option to buy up to 1,304,348 additional common shares at the public offering price, less discounts and commissions.
Beta Bionics expects to use net proceeds for general corporate purposes, including commercialization of Mint, manufacturing expansion, R&D and clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses. J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are joint book-running managers, and the securities are being issued under an effective Form S-3 shelf registration.
Beta Bionics (BBNX) plans an underwritten public offering of $125.0 million of common stock, subject to market and other conditions.
All shares in the base deal will be sold by the company, and Beta Bionics intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of common stock. The company states there is no assurance the offering will be completed or on what terms. Net proceeds are expected to be used for general corporate purposes, including commercialization of Mint™, expansion of manufacturing, research and clinical development, product enhancements, potential strategic opportunities, and working capital.
Beta Bionics (BBNX) received FDA clearance for Mint, a reusable/disposable patch insulin pump that integrates with leading CGMs and allows iOS/Android smartphone control.
Mint’s full U.S. commercial launch is expected in Q1 2027, with manufacturing capacity anticipated at a minimum of 1.5 million disposable units in 2027. At launch, Mint is expected to be available exclusively via the pharmacy channel, with about 40% of insured U.S. lives initially able to access it, rising to at least 50% within the first year. The company also unveiled its next-generation insulin dosing algorithm, 3D Intelligence, submitted to the FDA via a 510(k) and intended to power iLet 3D and Mint 3D, with U.S. commercialization targeted by end of 2026 and Q1 2027 respectively, subject to regulatory clearance.
Full-year 2026 revenue guidance is updated to $121–$126 million, down from $131–$136 million, reflecting a potential up to $10 million Q4 2026 deferral as some new iLet users may wait for Mint. The company reiterates 2026 expectations for 37%–39% of new patient starts reimbursed through the pharmacy channel and a 58.5%–59.5% gross margin. Mint is expected to be modestly dilutive to 2027 gross margin but highly accretive to long-term margins at scale.
Senseonics (SENS) and Beta Bionics (BBNX) have formed a strategic partnership to integrate the year-long Eversense® 365 continuous glucose monitoring system with the iLet® Bionic Pancreas automated insulin delivery platform.
The integrated system is intended to pair implantable, up-to-365-day glucose sensing with fully adaptive insulin dosing that does not require carb counting*, aiming to simplify diabetes management and broaden AID choices for adults with diabetes. Senseonics expects development of the Eversense 365–iLet integration to be completed in the fourth quarter of 2026, with commercial launch planned thereafter, subject to required testing, validation and applicable regulatory requirements. Interested individuals can sign up to receive updates and information on potential early access opportunities.
Beta Bionics (Nasdaq: BBNX) reported second quarter 2026 net sales of $32.0 million, a 38% increase from $23.2 million a year earlier, driven by 153% growth in the Pharmacy Benefit Plan (PBP) channel to $11.6 million and 9% growth in the DME channel to $20.4 million.
Gross margin improved to 59.0%, up 524 basis points year over year. The company recorded a net loss of $23.4 million (negative 73% of sales) versus $16.9 million, and adjusted EBITDA of negative $17.7 million versus negative $14.5 million. Cash, cash equivalents, and investments totaled $225.2 million at June 30, 2026. For full year 2026, Beta Bionics maintained revenue guidance of $131–$136 million, kept PBP new-start mix guidance unchanged, and raised gross margin guidance to 58.5–59.5%. The company also initiated a pivotal U.S. trial of iLet in adults with type 2 diabetes and outlined plans to fully commercialize its Mint patch pump by the end of the second quarter of 2027, both subject to FDA clearance.
Beta Bionics (Nasdaq: BBNX) plans to release its Q2 2026 financial results after market close on Wednesday, July 29, 2026. Management will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to review quarterly performance.
Beta Bionics (Nasdaq: BBNX) launched a public, near real-time real-world data dashboard for its iLet Bionic Pancreas at betabionics.com/hcp/real-world-data.
The dashboard shows outcomes for all iLet users meeting two criteria: provider-reported baseline HbA1c and at least two weeks of cloud-uploaded data, with no exclusions, plus a companion guide to help clinicians evaluate AID system data.